Bispecific antibodies: unleashing a new era in oncology treatment.

Mol Cancer · 2025 · PMC12320366 · PMID 40760704

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients in the dose-reduced cohort also showed a trend toward less T-cell exhaustion, which may indicate improved immune fitness for T-cell redirecting therapies [ 232 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.